A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19/ALLO-501
Condition(s)
Leukemia Lymphoma
Leukemia Lymphoma
Age Group
0-9 years 10-17 years 18-26 years 27 years and older
0-9 years 10-17 years 18-26 years 27 years and older
Phase(s)
1
1
Biological
UCART19/ALLO-501 follow-up
Trial Summary & Details
Ages: Child, Adult, Older Adult
Condition: Advanced Lymphoid Malignancies
Condition: Advanced Lymphoid Malignancies
The purpose of this study is to evaluate the long-term safety and efficacy of UCART19/ALLO-501 administration to patients with advanced lymphoid malignancies.